Revenues of €17.5 million for the full year of 2023, compared to €12.2 million for 2022Cash and cash equivalents at €26.9 million, short-term deposits at €.
Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million2, and long-term deposit at €9.3 million3 as of June 30, 2023, compared to.
Daix (France), Long Island City (New York, United States), June 24, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical.
Lanifibranor 800mg achieved the primary efficacy endpoint demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance spectroscopy.